[HTML][HTML] NF-κB in innate neuroprotection and age-related neurodegenerative diseases

A Lanzillotta, V Porrini, A Bellucci, M Benarese… - Frontiers in …, 2015 - frontiersin.org
A Lanzillotta, V Porrini, A Bellucci, M Benarese, C Branca, E Parrella, PF Spano, M Pizzi
Frontiers in neurology, 2015frontiersin.org
NF-κB factors are cardinal transcriptional regulators of inflammation and apoptosis, involved
in the brain programing of systemic aging and in brain damage. The composition of NF-κB
active dimers and epigenetic mechanisms modulating histone acetylation, finely condition
neuronal resilience to brain insults. In stroke models, the activation of NF-κB/c-Rel promotes
neuroprotective effects by transcription of specific anti-apoptotic genes. Conversely, aberrant
activation of NF-κB/RelA showing reduced level of total acetylation, but site-specific …
NF-κB factors are cardinal transcriptional regulators of inflammation and apoptosis, involved in the brain programing of systemic aging and in brain damage. The composition of NF-κB active dimers and epigenetic mechanisms modulating histone acetylation, finely condition neuronal resilience to brain insults. In stroke models, the activation of NF-κB/c-Rel promotes neuroprotective effects by transcription of specific anti-apoptotic genes. Conversely, aberrant activation of NF-κB/RelA showing reduced level of total acetylation, but site-specific acetylation on lysine 310, triggers the expression of pro-apoptotic genes. Constitutive knockout of c-Rel shatters the resilience of substantia nigra (SN) dopaminergic (DA) neurons to aging and induces a parkinsonian like pathology in mice. c-rel−/− mice show increased level of aberrantly acetylated RelA in the basal ganglia, neuroinflammation, accumulation of alpha-synuclein, and iron. Moreover, they develop motor deficits responsive to l-DOPA treatment and associated with loss of DA neurons in the SN. Here, we discuss the effect of unbalanced activation of RelA and c-Rel during aging and propose novel challenges for the development of therapeutic strategies in neurodegenerative diseases.
Frontiers